Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig

被引:12
作者
Moses, D [1 ]
Gross, A [1 ]
Finberg, JPM [1 ]
机构
[1] Technion Israel Inst Technol, Rappaport Family Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel
关键词
rasagiline; 6-hydroxydopamine; Parkinson's disease; monoamine oxidase;
D O I
10.1016/j.neuropharm.2004.02.016
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The modification of L-3,4-dihydrooxyphenylalanine- (L-DOPA-) induced turning response by the new selective monoamine oxidase type B (MAO-B) inhibitor rasagiline was studied in guinea-pigs bearing a unilateral 6-hydroxydopamine-induced lesion in the substantia nigra. In an initial experiment, it was established that contralateral turning is induced in lesioned guinea-pigs in response to apomorphine (18 mg/kg i.p.) and L-DOPA/carbidopa (15/3.5 mg/kg i.p.), while ipsilateral turning is induced by S(+)-methamphetamine (7 mg/kg i.p.). The effect of rasagiline was studied in a chronic treatment regimen, in which animals were treated with rasagiline (0.05 mg/kg s.c.) or saline s.c. daily commencing 2 weeks after lesioning, and L-DOPA/carbidopa (4:1 mg/kg) was administered once daily for 21 days. Only guinea-pigs with 95% or more depletion of striatal dopamine were included in this study. Guinea-pigs treated with rasagiline had a significantly increased intensity and duration of turning in response to L-DOPA (P < 0.05 by repeated measures ANOVA) over the 21-day period. On day 21. turning averaged 806 +/- 105 (n = 10) vs 442 +/- 123 (n = 11) turns per 180 min for rasagiline and vehicle treated animals, respectively (P < 0.05); turning duration half-time averaged 81 +/- 15.4 (n = 10) as opposed to 33 +/- 7.6 (n = 11) min for rasagiline and vehicle treatments (P < 0.01). Concentration of dopamine in intact striatum was significantly increased (69.3 +/- 2.1 and 60.3 +/- 2.4 pmol/mg tissue for rasagiline and vehicle, P < 0.05) and levels of dihydroxyphenylacetic acid and homovanillic acid were decreased by the rasagiline treatment. Activity of brain MAO-B was 8.6 +/- 2.9%, and MAO-A was 71 +/- 1.5% that of control in rasagiline-treated animals. Chronic, selective inhibition of MAO-B by rasagiline potentiated L-DOPA-induced turning in this rodent model. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:72 / 80
页数:9
相关论文
共 41 条
[1]   GUINEA-PIG STRIATUM AS A MODEL OF HUMAN DOPAMINE DEAMINATION - THE ROLE OF MONOAMINE-OXIDASE ISOZYME RATIO, LOCALIZATION, AND AFFINITY FOR SUBSTRATE IN SYNAPTIC DOPAMINE METABOLISM [J].
AZZARO, AJ ;
KING, J ;
KOTZUK, J ;
SCHOEPP, DD ;
FROST, J ;
SCHOCHET, S .
JOURNAL OF NEUROCHEMISTRY, 1985, 45 (03) :949-956
[3]   Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models [J].
Bibbiani, F ;
Oh, JD ;
Chase, TN .
NEUROLOGY, 2001, 57 (10) :1829-1834
[4]   COMPARATIVE-STUDY OF SELEGILINE PLUS L-DOPA-CARBIDOPA VERSUS L-DOPA-CARBIDOPA ALONE IN THE TREATMENT OF PARKINSONS-DISEASE [J].
BRANNAN, T ;
YAHR, MD .
ANNALS OF NEUROLOGY, 1995, 37 (01) :95-98
[5]   CHRONIC L-DOPA TREATMENT IN THE UNILATERAL 6-OHDA RAT - EVIDENCE FOR BEHAVIORAL SENSITIZATION AND BIOCHEMICAL TOLERANCE [J].
CAREY, RJ .
BRAIN RESEARCH, 1991, 568 (1-2) :205-214
[6]   Rotational behavior in dopamine nigrostriatal denervated rats:: Effects of a wide range of time intervals between apomorphine administrations [J].
Casas, M ;
Prat, G ;
Robledo, P ;
Jané, F .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1999, 62 (03) :481-485
[7]   Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys [J].
DiMonte, DA ;
DeLanney, LE ;
Irwin, I ;
Royland, JE ;
Chan, P ;
Jakowec, MW ;
Langston, JW .
BRAIN RESEARCH, 1996, 738 (01) :53-59
[8]   EXCITATORY AMINO-ACID RECEPTOR ANTAGONISTS MODIFY REGIONAL CEREBRAL METABOLIC RESPONSES TO LEVODOPA IN 6-HYDROXYDOPAMINE-LESIONED RATS [J].
ENGBER, TM ;
ANDERSON, JJ ;
BOLDRY, RC ;
PAPA, SM ;
KUO, S ;
CHASE, TN .
NEUROSCIENCE, 1994, 59 (02) :389-399
[9]  
Finberg JPM, 1996, J NEURAL TRANSM-SUPP, P95
[10]  
FINBERG JPM, 1995, J NEUROCHEM, V65, P1213